Drug Profile
Research programme: respiratory virus therapeutics - Ansun Biopharma
Alternative Names: ANSX EV68; ANSX MP10; ANSX RV14; AXSXS68; Inviridin; NEX-PIN; NEX-VAC; ViracidinLatest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator NexBio
- Developer Ansun Biopharma
- Class Recombinant fusion proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Enterovirus infections; Metapneumovirus infections
- Discontinued Influenza virus infections; Respiratory syncytial virus infections
Most Recent Events
- 28 Dec 2022 Discontinued - Preclinical for Respiratory syncytial virus infections in USA (unspecified route)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections in USA
- 28 Aug 2019 No recent reports of development identified for preclinical development in Enterovirus infections in USA